These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. Macchia PE; Bagattini M; Lupoli G; Vitale M; Vitale G; Fenzi G J Endocrinol Invest; 2001 Mar; 24(3):152-8. PubMed ID: 11314743 [TBL] [Abstract][Full Text] [Related]
45. Therapeutic responses to corticosteroids in Graves' ophthalmopathy. Chang TC; Kao SC; Hsiao YL; Lu CP; Huang KM; Tzeng SS J Formos Med Assoc; 1996 Nov; 95(11):833-8. PubMed ID: 8990770 [TBL] [Abstract][Full Text] [Related]
46. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy. Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305 [TBL] [Abstract][Full Text] [Related]
48. [Steroid therapy for Graves' ophthalmopathy]. Hiromatsu Y Nihon Rinsho; 2006 Dec; 64(12):2279-85. PubMed ID: 17154092 [TBL] [Abstract][Full Text] [Related]
49. Interleukin 18 and transforming growth factor beta1 in the serum of patients with Graves' ophthalmopathy treated with corticosteroids. Myśliwiec J; Kretowski A; Stepień A; Mirończuk K; Kinalska I Int Immunopharmacol; 2003 Apr; 3(4):549-52. PubMed ID: 12689659 [TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy. Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of the patients with Grave's ophthalmopathy after the corticosteroids treatment. Petrović MJ; Sarenac T; Srećković S; Petrović M; Vulović D; Janićijević K Vojnosanit Pregl; 2012 Mar; 69(3):249-52. PubMed ID: 22624411 [TBL] [Abstract][Full Text] [Related]
52. Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids. Myśliwiec J; Kretowski A; Szelachowska M; Topolska J; Mikita A; Kinalska I Immunol Lett; 2001 Oct; 78(3):123-6. PubMed ID: 11578685 [TBL] [Abstract][Full Text] [Related]
53. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy. Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088 [TBL] [Abstract][Full Text] [Related]
54. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves' ophthalmopathy: a prospective, randomized controlled trial. He Y; Mu K; Liu R; Zhang J; Xiang N Endocr J; 2017 Feb; 64(2):141-149. PubMed ID: 27853049 [TBL] [Abstract][Full Text] [Related]
55. Quality of life assessment in patients with Graves' disease and progressive infiltrative ophthalmopathy during combined treatment with methylprednisolone and orbital radiotherapy. Kulig G; Andrysiak-Mamos E; Sowińska-Przepiera E; Kulig J; Karakiewicz B; Brodowski J; Robaczyk M; Homa K; Letkiewicz M; Syrenicz A Endokrynol Pol; 2009; 60(3):158-65. PubMed ID: 19569015 [TBL] [Abstract][Full Text] [Related]
56. Application of digital infrared thermal imaging in determining inflammatory state and follow-up effect of methylprednisolone pulse therapy in patients with Graves' ophthalmopathy. Chang TC; Hsiao YL; Liao SL Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):45-9. PubMed ID: 17653750 [TBL] [Abstract][Full Text] [Related]